Recently, "Women's Health Dev," a world-class authoritative journal in the field of women's health, published an article entitled "DE-T1 on the Blastocyst obtained Rate and Live Birth Rates in Women Receiving IVF-ET Treatment". The research results confirmed that DE-T1 could significantly improve the blastocyst acquisition rate and live birth rate in female IVF treatment.

Previously, the authoritative medical journal "International Journal of Molecular Medicine" published an explanation that DE-T1 could increase the number of reproductive hormone receptors.

In 2018, the "Chinese Medical Journal" also published: Dandelion T-1 extract on ovarian granulosa cell proliferation and hormone receptor expression by Beijing Obstetrics and Gynecology Hospital's reproductive expert team. The clinical experiment confirmed: that Dandelion T-1  can promote the proliferation of granulosa cells and increase the activity of reproductive hormone receptors.

Based on previous research and clinical practice, Dr. Shao's team conducted a retrospective cohort study to analyze 1,014 patients for eight years and confirmed that DE-T1 could significantly improve the blastocyst acquisition rate and live birth rate in female IVF treatment.

Women of different ages and AMH can all benefit from taking Shawkea DE-T1. The analysis believes that the increase in blastocyst acquisition rate is based on the fact that DE-T1 can promote the proliferation of granulosa cells and increase the activity of reproductive hormone receptors.

The improvement of the live birth rate through DE-T1 was achieved by its two effects, increasing the number and quality of blastocysts.

Reproduction is a complex physiological process, and the mechanism by which DE-T1 achieves multi-target synergy on the hypothalamus, pituitary, ovary, uterus, and other organs still needs further study.

If you are interested in reading the published paperwork, please contact us by contact@shawkea-usa.com.

近日，世界级女性健康领域权威期刊《Women's Health Dev》刊登了日本英医院邵辉博士团队与中国生殖医学界专家团队的一篇题为“DE-T1 on the Blastocyst obtained Rate and Live Births Rates in Women Receiving IVF-ET Treatment”的研究论文，该研究结果科学证实：DE-T1可显著提升女性IVF治疗中囊胚获得率与活产率。

在此前，医学界权威期刊《International Journal of Molecular Medicine》发表阐释了DE-T1可以提高生殖激素受体的数量。

2018年《中华医学杂志》也相继刊登了：北京妇产医院生殖专家团队发表的题为：蒲公英T-1提取物对卵巢颗粒细胞增殖及激素受体表达的研究，该临床实验证实：蒲公英T-1可以促进颗粒细胞增殖及提高生殖激素受体活性。

在前期研究与临床实践的基础上，邵博士团队历经8年时间，采用回顾性队列研究分析1014例患者，证实DE-T1可显著提升女性IVF治疗中囊胚获得率与活产率。

不同年龄与AMH女性均可获益，分析认为囊胚获得率的提升是基于DE-T1可以促进颗粒细胞增殖及提高生殖激素受体的活性。

DE-T1对活产率的改善是经由其提升囊胚获取数量与改善囊胚质量两方面作用实现的。

生殖是一个复杂的生理过程， DE-T1对下丘脑、垂体、卵巢、子宫和其他器官实现多靶点协同作用的机制仍需要进一步研究。